Oncologist-led germline genetic testing for uveal melanoma

ABSTRACT Purpose To report the genotype and phenotype of a cohort of unselected uveal melanoma (UM) patients who had germline multi-gene panel genetic testing, including the BAP1 gene, from a large multi-ethnic cancer centre. We describe the central role of the medical genetics clinic in collaboration with oncologists in a mainstreaming model to facilitate genetic testing, counselling and streamlining of patients with hereditary cancer predisposition. Methods A retrospective chart review of clinical and genetic findings of unselected UM patients who had germline genetic testing between December 2019 and October 2021 was conducted. Extracted DNA from peripheral blood samples were analyzed with a multi-gene panel that included at least six genes associated with hereditary melanoma. The correlation between the genotype and the phenotype of the cohort was evaluated. Statistical analysis comprised descriptive and comparative statistics with significance assigned at p < .05. The genetics clinic streamlined patients among the relevant oncology clinics for cancer screening in germline BAP1 positive individuals. Results In unselected UM patients, 3.5% (4/114) tested positive for a BAP1 pathogenic variant. Germline BAP1 status was associated with a family history of mesothelioma (p = .0015) and metastatic disease (p = .017). There were no other significant associations between the patient- or tumour-related characteristics and germline BAP1 results. Conclusion A germline BAP1 mutation was detected in 3.5% of unselected UM patients. The oncologist-initiated and genetics-led mainstreaming model is a straightforward process and can be utilized for offering genetic testing to all UM patients.

[1]  T. Yanes,et al.  Protocol to evaluate a pilot program to upskill clinicians in providing genetic testing for familial melanoma , 2022, PloS one.

[2]  R. Zweemer,et al.  Mainstream genetic testing for women with ovarian cancer provides a solid basis for patients to make a well-informed decision about genetic testing , 2022, Hereditary cancer in clinical practice.

[3]  G. Scagliotti,et al.  Diagnostics of BAP1-Tumor Predisposition Syndrome by a Multitesting Approach: A Ten-Year-Long Experience , 2022, Diagnostics.

[4]  R. Kim,et al.  A Comparison of Patient-Reported Outcomes Following Consent for Genetic Testing Using an Oncologist- or Genetic Counselor-Mediated Model of Care , 2021, Current oncology.

[5]  N. Hayward,et al.  Microsimulation Model for Evaluating the Cost-Effectiveness of Surveillance in BAP1 Pathogenic Variant Carriers. , 2021, JCO clinical cancer informatics.

[6]  Jenna Scott,et al.  The Canadian genetic counseling workforce: Perspectives from employers and recent graduates , 2020, Journal of genetic counseling.

[7]  M. Carlo,et al.  BAP1 Tumor Predisposition Syndrome , 2020, Uveal Melanoma.

[8]  H. Pickett,et al.  Loss-of-function variants in POT1 predispose to uveal melanoma , 2020, Journal of Medical Genetics.

[9]  W. Foulkes,et al.  BRCA testing in women with high-grade serous ovarian cancer: gynecologic oncologist-initiated testing compared with genetics referral , 2020, International Journal of Gynecological Cancer.

[10]  L. Lynd,et al.  The composition and capacity of the clinical genetics workforce in high-income countries: a scoping review , 2020, Genetics in Medicine.

[11]  N. Rahman,et al.  Oncologist-led BRCA ‘mainstreaming’ in the ovarian cancer clinic: A study of 255 patients and its impact on their management , 2020, Scientific Reports.

[12]  A. Karsan,et al.  Oncology Clinic-Based Hereditary Cancer Genetic Testing in a Population-Based Health Care System , 2020, Cancers.

[13]  T. Walsh,et al.  Whole Exome Sequencing Identifies Candidate Genes Associated with Hereditary Predisposition to Uveal Melanoma. , 2019, Ophthalmology.

[14]  A. V. D. van den Ouweland,et al.  Families with BAP1-Tumor Predisposition Syndrome in The Netherlands: Path to Identification and a Proposal for Genetic Screening Guidelines , 2019, Cancers.

[15]  V. Raivio,et al.  Population-based analysis of BAP1 germline variations in patients with uveal melanoma. , 2019, Human molecular genetics.

[16]  B. Taylor,et al.  Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  Nazneen Rahman,et al.  Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer , 2019, JAMA network open.

[18]  Joshua L. Deignan,et al.  Patient re-contact after revision of genomic test results: points to consider—a statement of the American College of Medical Genetics and Genomics (ACMG) , 2018, Genetics in Medicine.

[19]  C. Shields,et al.  Overview of BAP1 cancer predisposition syndrome and the relationship to uveal melanoma , 2018, Journal of current ophthalmology.

[20]  Gloria S. Huang,et al.  Evaluation of a Streamlined Oncologist-Led BRCA Mutation Testing and Counseling Model for Patients With Ovarian Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  R. Bennett,et al.  Projecting the Supply and Demand for Certified Genetic Counselors: a Workforce Study , 2018, Journal of Genetic Counseling.

[22]  M. Rehman,et al.  Germline BAP1 alterations in familial uveal melanoma , 2017, Genes, chromosomes & cancer.

[23]  Suzanne Miller,et al.  New paradigms for BRCA1/BRCA2 testing in women with ovarian cancer: results of the Genetic Testing in Epithelial Ovarian Cancer (GTEOC) study , 2016, Journal of Medical Genetics.

[24]  V. Raivio,et al.  BAP1 Germline Mutations in Finnish Patients with Uveal Melanoma. , 2016, Ophthalmology.

[25]  S. Seal,et al.  Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients , 2016, Scientific Reports.

[26]  M. Abdel-Rahman,et al.  Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases , 2016, Clinical genetics.

[27]  N. Rahman,et al.  A cost analysis of a cancer genetic service model in the UK , 2015, bioRxiv.

[28]  Jiali Han,et al.  MC1R variants increased the risk of sporadic cutaneous melanoma in darker‐pigmented Caucasians: A pooled‐analysis from the M‐SKIP project , 2014, International journal of cancer.

[29]  Ivana K. Kim,et al.  Clinical Characteristics of Uveal Melanoma in Patients With Germline BAP1 Mutations. , 2014, JAMA ophthalmology.

[30]  X. Hua,et al.  Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma , 2014, Nature Genetics.

[31]  C. Shields,et al.  American Joint Committee on Cancer classification of posterior uveal melanoma (tumor size category) predicts prognosis in 7731 patients. , 2013, Ophthalmology.

[32]  N. Hayward,et al.  Prevalence of germline BAP1 mutation in a population‐based sample of uveal melanoma cases , 2013, Pigment cell & melanoma research.

[33]  L. Thomas,et al.  Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants , 2013, Journal of Medical Genetics.

[34]  Sofia Khan,et al.  Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations , 2012, Familial Cancer.

[35]  Ivana K. Kim,et al.  Germline BAP1 Inactivation Is Preferentially Associated with Metastatic Ocular Melanoma and Cutaneous-Ocular Melanoma Families , 2012, PloS one.

[36]  C. Eng,et al.  Lifetime Cancer Risks in Individuals with Germline PTEN Mutations , 2012, Clinical Cancer Research.

[37]  C. Cruz,et al.  Uveal melanoma and BRCA1/BRCA2 genes: a relationship that needs further investigation. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  K. Brown,et al.  A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma , 2011, Nature.

[39]  M. Abdel-Rahman,et al.  Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers , 2011, Journal of Medical Genetics.

[40]  J. Becker,et al.  Germline mutations in BAP1 predispose to melanocytic tumors , 2011, Nature Genetics.

[41]  N. Cox,et al.  Germline BAP1 mutations predispose to malignant mesothelioma , 2011, Nature Genetics.

[42]  A. Bowcock,et al.  Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas , 2010, Science.

[43]  D. Elder,et al.  Does MC1R genotype convey information about melanoma risk beyond risk phenotypes? , 2010, Cancer.

[44]  F. Sera,et al.  MC1R variants, melanoma and red hair color phenotype: A meta‐analysis , 2008, International journal of cancer.

[45]  R. Millikan,et al.  Population-based study of natural variation in the melanocortin-1 receptor gene and melanoma. , 2006, Cancer research.

[46]  James E. Morrow.  The University of Washington , 2004 .

[47]  G. Lenoir,et al.  CDKN2A as a uveal and cutaneous melanoma susceptibility gene , 2003, Genes, chromosomes & cancer.

[48]  J. Keunen,et al.  Characterization of melanocortin-1 receptor gene variants in uveal melanoma patients. , 2001, Investigative ophthalmology & visual science.

[49]  J. Hansson,et al.  CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas. , 2000, Cancer research.

[50]  S. Seal,et al.  Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. , 1994, Science.

[51]  E. Gragoudas,et al.  Familial uveal melanoma. , 1994, American journal of ophthalmology.

[52]  M. King,et al.  Linkage of early-onset familial breast cancer to chromosome 17q21. , 1990, Science.

[53]  N. Hayward,et al.  Prolonged stable disease in a uveal melanoma patient with germline MBD4 nonsense mutation treated with pembrolizumab and ipilimumab , 2019, Immunogenetics.

[54]  R. Glynn,et al.  Epidemiologic aspects of uveal melanoma. , 1988, Survey of ophthalmology.